Jamjoom Pharmaceuticals Factory Company (TADAWUL:4015)

Saudi Arabia flag Saudi Arabia · Delayed Price · Currency is SAR
134.20
+1.50 (1.13%)
Mar 5, 2026, 3:16 PM AST
-19.45%
Market Cap 9.39B
Revenue (ttm) 1.46B
Net Income (ttm) 447.34M
Shares Out 70.00M
EPS (ttm) 6.39
PE Ratio 21.00
Forward PE 18.26
Dividend 3.06 (2.28%)
Ex-Dividend Date Mar 2, 2026
Volume 72,894
Average Volume 98,995
Open 133.00
Previous Close 132.70
Day's Range 132.80 - 136.10
52-Week Range 125.00 - 183.80
Beta 0.50
RSI 50.47
Earnings Date Feb 24, 2026

About TADAWUL:4015

Jamjoom Pharmaceuticals Factory Company, together with its subsidiaries, engages in the manufacture and distribution of pharmaceutical and consumer products in the Kingdom of Saudi Arabia, Gulf, Iraq, Egypt, North Africa, and internationally. The company offers human medicines; nutraceuticals; antibiotics; general analgesics; medicines for treatment of cough, allergy, asthma, heart diseases, blood pressure, diarrhea, vomiting, and ulcer and acidity; treatment of various skin infections and cancer diseases; and eye drops, and ointments and cosme... [Read more]

Sector Healthcare
Founded 1994
Country Saudi Arabia
Stock Exchange Saudi Stock Exchange
Ticker Symbol 4015
Full Company Profile

Financial Performance

In 2024, TADAWUL:4015's revenue was 1.32 billion, an increase of 19.77% compared to the previous year's 1.10 billion. Earnings were 356.52 million, an increase of 21.93%.

Financial Statements

News

There is no news available yet.